GlaxoSmithKline's Shingrix supply will vault upward, CEO says—in 2024, that is

GlaxoSmithKline has been laboring to boost supplies of next-gen shingles vaccine Shingrix, thanks to a speedy launch that bested all expectations. While it's planning a slight increase next year, the real "step change" will come in 2024 with a brand-new facility, CEO Emma Walmsley recently said.